Halozyme Therapeutics Inc (HALO)

Pretax margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	348,306	317,922	289,892	226,747	248,918	232,937	233,336	294,841	248,518	266,957	229,121	163,480	129,302	21,593	-39,679	-80,161	-72,251	-39,600	-42,448	-50,701
Revenue (ttm)	US$ in thousands	810,397	762,509	752,443	685,200	643,040	566,152	478,768	464,176	435,810	457,564	408,802	329,314	267,594	199,556	180,470	164,397	195,992	202,559	181,885	177,939
Pretax margin		42.98%	41.69%	38.53%	33.09%	38.71%	41.14%	48.74%	63.52%	57.02%	58.34%	56.05%	49.64%	48.32%	10.82%	-21.99%	-48.76%	-36.86%	-19.55%	-23.34%	-28.49%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $348,306K ÷ $810,397K
= 42.98%

The pretax margin of Halozyme Therapeutics Inc. has shown some fluctuations over the past eight quarters. The company's pretax margin was relatively stable between Q4 2022 and Q2 2023, with values ranging from 37.71% to 40.73%. However, there was a significant decline in Q1 2023 to 32.16%, followed by a rebound to 42.01% in Q4 2023.

The highest pretax margin was recorded in Q1 2022 at 62.52%, while the lowest was in Q1 2023 at 32.16%. Overall, the pretax margin has shown some variability, indicating potential changes in the company's profitability and efficiency in generating earnings before tax. Further analysis would be required to assess the factors contributing to these fluctuations.